AXL activation promotes adaptive resistance to KRAS-G12C inhibitors in KRASG12C-mutated non-small cell lung cancer

被引：0
作者：
Morimoto, Kenji
Yamada, Tadaaki
Hirai, Soichi
Katayama, Yuki
Kunimasa, Kei
Sasaki, Takaaki
Nishida, Makoto
Watanabe, Satoshi
Shiotsu, Shinsuke
Uehara, Hisanori
Takayama, Koichi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1941
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1941
引用
收藏
页数：2
相关论文
共 50 条
  • [21] KRAS G12C mutations in non-small cell lung cancer
    Li, J. J.
    Wu, X. J.
    Farzin, M.
    Bray, V.
    Williamson, J.
    Pal, A.
    Yip, P. Y.
    Hagelamin, A.
    Ding, P.
    Nindra, U.
    Vinod, S.
    French, B.
    Chua, W.
    Gupta, R.
    Cooper, W. A.
    Wang, B.
    Lee, C. S.
    HISTOPATHOLOGY, 2024, 85 : 25 - 25
  • [22] KRAS inhibitor-resistance in MET-amplified KRASG12C non-small cell lung cancer
    Suzuki, Shinichiro
    Yonesaka, Kimio
    CANCER SCIENCE, 2022, 113 : 1260 - 1260
  • [23] Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer
    Pellini, B.
    Ganesan, V.
    Wan, F.
    Sankararaman, S.
    Manyanont, S.
    Akhave, N.
    Baggstrom, M.
    Ward, J.
    Waqar, S.
    Morgensztern, D.
    Govindan, R.
    Devarakonda, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S209 - S210
  • [24] Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
    Ernst, S. M.
    de Bruijn, P.
    van der Horst, T. E.
    Paats, M. S.
    Aerts, J. G.
    Mathijssen, R. H.
    Koolen, S. L.
    Dingemans, A-M. C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [25] WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
    Yamamoto, Gaku
    Tanaka, Kosuke
    Kamata, Ryo
    Saito, Hitoshi
    Yamamori-Morita, Tomoko
    Nakao, Takehiro
    Liu, Jie
    Mori, Shunta
    Yagishita, Shigehiro
    Hamada, Akinobu
    Shinno, Yuki
    Yoshida, Tatsuya
    Horinouchi, Hidehito
    Ohe, Yuichiro
    Watanabe, Shun-Ichi
    Yatabe, Yasushi
    Kitai, Hidenori
    Konno, Satoshi
    Kobayashi, Susumu S.
    Ohashi, Akihiro
    CANCER LETTERS, 2025, 611
  • [26] The KRYSTAL-1 study of adagrasib - a new trial for KRASG12C-mutated non-small-cell lung cancer
    Murciano-Goroff, Yonina R.
    Lito, Piro
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (11) : 677 - 678
  • [27] The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer
    Yonina R. Murciano-Goroff
    Piro Lito
    Nature Reviews Clinical Oncology, 2022, 19 : 677 - 678
  • [28] The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
    Notario Rincon, L.
    Pous, A.
    Lopez-Paradis, A.
    Cerda, G.
    Cucurull, M.
    Hernandez, A.
    Domenech, M.
    Carcereny, E.
    Moran Bueno, M. T.
    Munoz, A.
    Mate, J. L.
    Sanz, C.
    Saigi, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S50 - S50
  • [29] Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer
    Hongyu Liu
    Chao Zhou
    Jun Lu
    Yuqing Liu
    Peichen Zou
    Liang Zhu
    Huimin Lei
    Baohui Han
    Cell Death & Disease, 16 (1)
  • [30] AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Fukui, Sarina
    Sawada, Ryo
    Tachibana, Yusuke
    Matsui, Yohei
    Nakamura, Ryota
    Ishida, Masaki
    Kawachi, Hayato
    Kunimasa, Kei
    Sasaki, Takaaki
    Nishida, Makoto
    Furuya, Naoki
    Watanabe, Satoshi
    Shiotsu, Shinsuke
    Nishioka, Naoya
    Horinaka, Mano
    Sakai, Toshiyuki
    Uehara, Hisanori
    Yano, Seiji
    Son, Bo-Kyung
    Tokuda, Shinsaku
    Takayama, Koichi
    CANCER LETTERS, 2024, 587
12345